Alx Oncology Holdings INC (ALXO) — SEC Filings

Overview

Alx Oncology Holdings INC (ALXO) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 17, 2026: On April 16, 2026, Barbara Klencke, a reporting person associated with ALX Oncology Holdings Inc., reported a change in beneficial ownership of securities. The filing details transactions related to her holdings, but specific dollar amounts and the exact nature of the transactions are not detailed i

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 31 neutral, 2 mixed. The dominant filing sentiment for Alx Oncology Holdings INC is neutral.

Filing Type Overview

Alx Oncology Holdings INC (ALXO) has filed 2 4, 14 8-K, 6 10-Q, 2 DEF 14A, 7 SC 13G/A, 2 SC 13G, 1 10-K, 1 SC 13D/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (35)

• ALX Oncology Holdings Inc. - Ownership Change Reported — 4 · Apr 17, 2026 Risk: low
  On April 16, 2026, Barbara Klencke, a reporting person associated with ALX Oncology Holdings Inc., reported a change in beneficial ownership of securities. The
• 8-K Filing — 8-K · Apr 13, 2026
• ALX Oncology: Jason Lettmann Reports Change in Ownership — 4 · Mar 23, 2026
  This Form 4 filing indicates that Jason Lettmann, a reporting person for ALX Oncology Holdings Inc., had a change in beneficial ownership of securities. While t
• ALX Oncology Narrows Q3 Loss Amidst R&D Cost Cuts — 10-Q · Nov 7, 2025 Risk: high
  ALX Oncology Holdings Inc. reported a net loss of $22.144 million for the three months ended September 30, 2025, a 27.9% improvement from the $30.707 million ne
• ALX Oncology Files 8-K: Director Changes and Officer Appointments — 8-K · Sep 12, 2025 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on September 11, 2025, reporting on the departure of directors, election of directors, appointment of officers, and comp
• ALX Oncology Narrows Q2 Loss by 34% Amid R&D Spend Cuts — 10-Q · Aug 12, 2025 Risk: high
  ALX Oncology Holdings Inc. reported a net loss of $25.949 million for the three months ended June 30, 2025, a significant improvement from the $39.399 million n
• ALX Oncology Holdings Inc. Files 8-K on Shareholder Vote Matters — 8-K · Jun 12, 2025 Risk: low
  ALX Oncology Holdings Inc. filed an 8-K on June 12, 2025, reporting on a submission of matters to a vote of security holders that occurred on June 11, 2025. The
• ALX Oncology Files Q1 2025 10-Q — 10-Q · May 8, 2025 Risk: medium
  ALX Oncology Holdings Inc. reported its first quarter 2025 results on May 8, 2025. The company's financial statements for the period ending March 31, 2025, are
• ALX Oncology Faces Delisting Notice — 8-K · Apr 25, 2025 Risk: high
  ALX Oncology Holdings Inc. filed an 8-K on April 25, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, effective
• ALX Oncology Executive Compensation Details Revealed — DEF 14A · Apr 21, 2025 Risk: low
  ALX Oncology Holdings Inc. filed a DEF 14A on April 21, 2025, detailing executive compensation for the fiscal years ending December 31, 2022, 2023, and 2024. Th
• ALX Oncology Files 8-K for Financials — 8-K · Mar 6, 2025 Risk: low
  ALX Oncology Holdings Inc. filed an 8-K on March 6, 2025, to report on its results of operations and financial condition, as well as to file financial statement
• ALX Oncology Reports Exit Costs and Officer Changes — 8-K · Mar 5, 2025 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on March 5, 2025, reporting on cost-associated exit or disposal activities and changes in directors and officers. The fi
• ALX Oncology Holdings Inc. Files 8-K with Board and Compensation Changes — 8-K · Jan 22, 2025 Risk: medium
  ALX Oncology Holdings Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. The filing also includes a
• ALX Oncology Holdings Inc. Reports Board and Executive Changes — 8-K · Jan 17, 2025 Risk: medium
  ALX Oncology Holdings Inc. announced on January 16, 2025, changes in its board of directors and executive compensation arrangements. The filing details the depa
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• ALX Oncology Holdings Inc. Announces Board Changes and Officer Compensation — 8-K · Nov 14, 2024 Risk: medium
  On November 8, 2024, ALX Oncology Holdings Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Michael J.
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• ALX Oncology Holdings Files Q3 2024 10-Q — 10-Q · Nov 7, 2024 Risk: medium
  ALX Oncology Holdings Inc. filed its 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months e
• SC 13G/A Filing — SC 13G/A · Oct 10, 2024
• ALX Oncology Files 8-K: Director Changes & Financials — 8-K · Oct 4, 2024 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on September 30, 2024, reporting on the departure of directors, election of new directors, appointment of officers, and
• SC 13G Filing — SC 13G · Aug 22, 2024
• SC 13G Filing — SC 13G · Aug 13, 2024
• ALX Oncology Holdings Q2 2024 Update — 10-Q · Aug 12, 2024 Risk: medium
  ALX Oncology Holdings Inc. reported its financial results for the quarter ended June 30, 2024. The company's filing details its financial position and operation
• ALX Oncology Holdings Inc. Files 8-K Report — 8-K · Aug 8, 2024 Risk: low
  On August 8, 2024, ALX Oncology Holdings Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as
• ALX Oncology Reports Director/Officer Changes — 8-K · Aug 6, 2024 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on August 5, 2024, reporting changes in its board of directors and certain officers, along with updates on compensatory
• ALX Oncology Holdings Reports Shareholder Vote Matters — 8-K · Jun 17, 2024 Risk: medium
  ALX Oncology Holdings Inc. filed an 8-K on June 17, 2024, reporting an event that occurred on June 12, 2024. This filing pertains to the submission of matters t
• ALX Oncology Holdings Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 9, 2024 Risk: medium
  ALX ONCOLOGY HOLDINGS INC (ALXO) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. ALX Oncology Holdings Inc. filed a 10-Q report for the period endi
• ALX Oncology Announces Executive and Board Changes — 8-K · May 2, 2024 Risk: medium
  ALX Oncology Holdings Inc. announced on April 28, 2024, changes in its board of directors and executive compensation. Specifically, Dr. Michael J. Yothers was a
• ALX Oncology Holdings Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 22, 2024 Risk: low
  ALX ONCOLOGY HOLDINGS INC (ALXO) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. ALX Oncology Holdings Inc. will hold its 2024 Annual Meeting
• ALX Oncology Holdings Inc. Files 2023 Annual Report on Form 10-K — 10-K · Mar 7, 2024 Risk: medium
  ALX ONCOLOGY HOLDINGS INC (ALXO) filed a Annual Report (10-K) with the SEC on March 7, 2024. ALX Oncology Holdings Inc. filed its annual report on Form 10-K for
• Lightstone Ventures Amends ALX Oncology Holdings Stake — SC 13D/A · Feb 14, 2024 Risk: medium
  LSV Associates, LLC, along with Lightstone Ventures entities and individuals Henry A. Plain, Jr., Jean M. George, and Michael A. Carusi, filed an Amendment No.
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• FMR LLC & Abigail Johnson Maintain 14.999% Stake in ALX Oncology — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in ALX Oncology Holdings Inc. (ALXO) to 14.999

Frequently Asked Questions